Wang Qiaolin, Lv Chengzhi, Han Xi, Shen Minxue, Kuang Yehong
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
National Clinical Research Center for Geriatric Disorders (Xiangya Hospital), Changsha, Hunan, People's Republic of China.
J Inflamm Res. 2021 Nov 27;14:6265-6273. doi: 10.2147/JIR.S341429. eCollection 2021.
Vaccination is one of the most important strategy to prevent infections and control epidemics, but it also raises concerns about safety in patients receiving treatments. This study aimed to investigate the rate and factors for unvaccination, as well as adverse reactions and deterioration of disease after SARS-CoV-2 vaccination in psoriatic patients.
A web-based questionnaire survey on SARS-CoV-2 vaccination, adverse reactions, and self-reported change of disease condition after vaccination in patients with psoriasis was conducted. Demographic, clinical, and psychological data were collected. Multivariable logistic regression was used in the estimation of associations.
A total of 788 psoriatic patients were investigated, and 68.9% reported SARS-CoV-2 vaccination. Younger age, use of interleukin-17 inhibitors, and symptoms of anxiety were associated with unvaccination. The incidence of overall adverse reactions after vaccination was 30.8%, and no severe adverse reaction was reported. The most common local and systemic adverse reactions were pain at the injection site and fatigue, respectively. Most patients reported no change in psoriasis after vaccination, while 16.6% and 4.4% reported slight and significant deteriorations of the disease, respectively. Nonadherence to treatment, symptoms of anxiety and depression, and perceived stress were associated with self-reported deterioration of psoriasis after vaccination.
While a favorable safety profile of SARS-CoV-2 vaccines is observed, receiving biologic treatment is factor for unvaccination in patients with psoriasis. Deterioration of psoriasis reported by a small proportion of patients is partially attributable to mental and behavioral factors.
接种疫苗是预防感染和控制疫情的最重要策略之一，但也引发了对接受治疗患者安全性的担忧。本研究旨在调查银屑病患者中未接种疫苗的比例及因素，以及接种新型冠状病毒疫苗后的不良反应和疾病恶化情况。
对银屑病患者进行了一项基于网络的关于新型冠状病毒疫苗接种、不良反应及接种后自我报告的疾病状况变化的问卷调查。收集了人口统计学、临床和心理数据。采用多变量逻辑回归来估计关联。
共调查了788例银屑病患者，68.9%的患者报告接种了新型冠状病毒疫苗。年龄较小、使用白细胞介素-17抑制剂以及焦虑症状与未接种疫苗有关。接种后总体不良反应发生率为30.8%，未报告严重不良反应。最常见的局部和全身不良反应分别是注射部位疼痛和疲劳。大多数患者报告接种疫苗后银屑病无变化，而分别有16.6%和4.4%的患者报告疾病有轻微和显著恶化。不坚持治疗、焦虑和抑郁症状以及感知压力与接种疫苗后自我报告的银屑病恶化有关。
虽然观察到新型冠状病毒疫苗具有良好的安全性，但接受生物治疗是银屑病患者未接种疫苗的一个因素。一小部分患者报告的银屑病恶化部分归因于心理和行为因素。
